Publication of impact on health-related quality of life from 3 year data with vosoritide. These data suggest that after 3 years of treatment, vosoritide demonstrates a…
Read MoreAchondroplasia is the most common skeletal dysplasia and is characterized by a variety of medical, functional and psychosocial challenges across the lifespan. There is variability in…
Read MoreDespite the recognized expertise of pediatric endocrinologists, children with skeletal dysplasias have not been consistently managed by these physicians. Growth-altering treatments have broadened the role of…
Read MoreAchondroplasia growth charts included in this article. Achondroplasia is the most common genetic skeletal disorder causing disproportionate short stature/dwarfism. Common additionalfeatures include spinal stenosis, midface retrusion,…
Read MoreConstitutional Growth Delay and Familial Short Stature: A Guide for Families What is Short Stature? Doctors usually define short stature based on standard growth charts, rather…
Read MoreA mini-review on cost-conscious growth-promoting treatment.
Read MorePES Drugs and Therapeutics and Ethics committees present guidelines for Growth Hormone and Insulin-like Growth Factor-I Treatment in Children and Adolescents: Growth Hormone Deficiency, Idiopathic Short Stature, and Primary Insulin-Like Growth Factor-I Deficiency.
Read MoreA review of published data regarding the use of aromatase inhibitors in pediatrics.
Read More